Changes in systolic blood pressure in dogs with pituitary dependent hyperadrenocorticism during the first year of trilostane treatment
Abstract Background Systemic hypertension (SH) is common in dogs and humans with hypercortisolism and can persist after treatment. Objectives To evaluate changes in prevalence of SH and systolic blood pressure (SBP) in dogs with pituitary‐dependent hyperadrenocorticism (PDH) during the first year of...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2021-01-01
|
| Series: | Journal of Veterinary Internal Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1111/jvim.15978 |
| _version_ | 1811251210040115200 |
|---|---|
| author | Paula García San José Carolina Arenas Bermejo Daniel Alonso‐Miguel Irene Clares Moral Pedro Cuesta‐Alvaro María Dolores Pérez Alenza |
| author_facet | Paula García San José Carolina Arenas Bermejo Daniel Alonso‐Miguel Irene Clares Moral Pedro Cuesta‐Alvaro María Dolores Pérez Alenza |
| author_sort | Paula García San José |
| collection | DOAJ |
| description | Abstract Background Systemic hypertension (SH) is common in dogs and humans with hypercortisolism and can persist after treatment. Objectives To evaluate changes in prevalence of SH and systolic blood pressure (SBP) in dogs with pituitary‐dependent hyperadrenocorticism (PDH) during the first year of trilostane treatment, its relationship with disease control and selected laboratory variables, and their response to antihypertensive treatment. Animals Fifty‐one dogs with PDH treated with trilostane Q12h. Methods Prospective case series study. Dogs were evaluated at diagnosis (T0) and 1, 3, 6, and 12 months (T12). Dogs were classified as nonhypertensive (SBP < 160 mm Hg) or hypertensive (SBP≥160 mm Hg) and subclassified according to target organ damage (TOD) risk. Hypertensive dogs were treated with benazepril and, if control of SH was not achieved, amlodipine was added. Results Prevalence of SH decreased from T0 (36/51) to T12 (17/37; P = .01). Changes in SBP during the study were influenced by the risk of TOD at T0. In severely hypertensive (SBP ≥ 180 mm Hg) dogs, the decrease in SBP was more pronounced whereas in normotensive (SBP < 140 mm Hg) dogs SBP increased slightly (P = .00). Blood pressure was not associated with disease control. Antihypertensive treatment was needed in 31/51 dogs, and in 13/31 dogs additional SH control with amlodipine was required. One third of nonhypertensive dogs at T0 required treatment with benazepril because SH developed during follow‐up. Conclusions and Clinical Importance In dogs with PDH, SBP should be measured at every visit, regardless of disease control or SBP at diagnosis. More than 1 drug may be necessary to manage SH in affected dogs. |
| first_indexed | 2024-04-12T16:17:07Z |
| format | Article |
| id | doaj.art-230f408ea4664d13ba626321209d869d |
| institution | Directory Open Access Journal |
| issn | 0891-6640 1939-1676 |
| language | English |
| last_indexed | 2024-04-12T16:17:07Z |
| publishDate | 2021-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Veterinary Internal Medicine |
| spelling | doaj.art-230f408ea4664d13ba626321209d869d2022-12-22T03:25:42ZengWileyJournal of Veterinary Internal Medicine0891-66401939-16762021-01-0135113014110.1111/jvim.15978Changes in systolic blood pressure in dogs with pituitary dependent hyperadrenocorticism during the first year of trilostane treatmentPaula García San José0Carolina Arenas Bermejo1Daniel Alonso‐Miguel2Irene Clares Moral3Pedro Cuesta‐Alvaro4María Dolores Pérez Alenza5Department of Animal Medicine and Surgery, Veterinary Faculty Complutense University of Madrid Madrid SpainAnicura Hospital Veterinario Valencia Sur Valencia SpainDepartment of Animal Medicine and Surgery, Veterinary Faculty Complutense University of Madrid Madrid SpainVeterinary Teaching Hospital Complutense, Complutense University of Madrid Madrid SpainComputing Services, Research Support Complutense University of Madrid Avda de la Complutense s/n Madrid SpainDepartment of Animal Medicine and Surgery, Veterinary Faculty Complutense University of Madrid Madrid SpainAbstract Background Systemic hypertension (SH) is common in dogs and humans with hypercortisolism and can persist after treatment. Objectives To evaluate changes in prevalence of SH and systolic blood pressure (SBP) in dogs with pituitary‐dependent hyperadrenocorticism (PDH) during the first year of trilostane treatment, its relationship with disease control and selected laboratory variables, and their response to antihypertensive treatment. Animals Fifty‐one dogs with PDH treated with trilostane Q12h. Methods Prospective case series study. Dogs were evaluated at diagnosis (T0) and 1, 3, 6, and 12 months (T12). Dogs were classified as nonhypertensive (SBP < 160 mm Hg) or hypertensive (SBP≥160 mm Hg) and subclassified according to target organ damage (TOD) risk. Hypertensive dogs were treated with benazepril and, if control of SH was not achieved, amlodipine was added. Results Prevalence of SH decreased from T0 (36/51) to T12 (17/37; P = .01). Changes in SBP during the study were influenced by the risk of TOD at T0. In severely hypertensive (SBP ≥ 180 mm Hg) dogs, the decrease in SBP was more pronounced whereas in normotensive (SBP < 140 mm Hg) dogs SBP increased slightly (P = .00). Blood pressure was not associated with disease control. Antihypertensive treatment was needed in 31/51 dogs, and in 13/31 dogs additional SH control with amlodipine was required. One third of nonhypertensive dogs at T0 required treatment with benazepril because SH developed during follow‐up. Conclusions and Clinical Importance In dogs with PDH, SBP should be measured at every visit, regardless of disease control or SBP at diagnosis. More than 1 drug may be necessary to manage SH in affected dogs.https://doi.org/10.1111/jvim.15978angiotensin converting enzyme inhibitorsbenazeprilcaninecortisolCushing'shypertension |
| spellingShingle | Paula García San José Carolina Arenas Bermejo Daniel Alonso‐Miguel Irene Clares Moral Pedro Cuesta‐Alvaro María Dolores Pérez Alenza Changes in systolic blood pressure in dogs with pituitary dependent hyperadrenocorticism during the first year of trilostane treatment Journal of Veterinary Internal Medicine angiotensin converting enzyme inhibitors benazepril canine cortisol Cushing's hypertension |
| title | Changes in systolic blood pressure in dogs with pituitary dependent hyperadrenocorticism during the first year of trilostane treatment |
| title_full | Changes in systolic blood pressure in dogs with pituitary dependent hyperadrenocorticism during the first year of trilostane treatment |
| title_fullStr | Changes in systolic blood pressure in dogs with pituitary dependent hyperadrenocorticism during the first year of trilostane treatment |
| title_full_unstemmed | Changes in systolic blood pressure in dogs with pituitary dependent hyperadrenocorticism during the first year of trilostane treatment |
| title_short | Changes in systolic blood pressure in dogs with pituitary dependent hyperadrenocorticism during the first year of trilostane treatment |
| title_sort | changes in systolic blood pressure in dogs with pituitary dependent hyperadrenocorticism during the first year of trilostane treatment |
| topic | angiotensin converting enzyme inhibitors benazepril canine cortisol Cushing's hypertension |
| url | https://doi.org/10.1111/jvim.15978 |
| work_keys_str_mv | AT paulagarciasanjose changesinsystolicbloodpressureindogswithpituitarydependenthyperadrenocorticismduringthefirstyearoftrilostanetreatment AT carolinaarenasbermejo changesinsystolicbloodpressureindogswithpituitarydependenthyperadrenocorticismduringthefirstyearoftrilostanetreatment AT danielalonsomiguel changesinsystolicbloodpressureindogswithpituitarydependenthyperadrenocorticismduringthefirstyearoftrilostanetreatment AT ireneclaresmoral changesinsystolicbloodpressureindogswithpituitarydependenthyperadrenocorticismduringthefirstyearoftrilostanetreatment AT pedrocuestaalvaro changesinsystolicbloodpressureindogswithpituitarydependenthyperadrenocorticismduringthefirstyearoftrilostanetreatment AT mariadoloresperezalenza changesinsystolicbloodpressureindogswithpituitarydependenthyperadrenocorticismduringthefirstyearoftrilostanetreatment |